Glypican 3型
肝细胞癌
医学
免疫毒素
癌症研究
嵌合抗原受体
免疫疗法
免疫系统
肿瘤科
免疫学
抗体
单克隆抗体
作者
Xiufeng Zheng,Xun Liu,Yanna Lei,Gang Wang,Ming Liu
标识
DOI:10.3389/fonc.2022.824208
摘要
Glypican-3 (GPC3) is a membrane-associated proteoglycan that is specifically up-regulated in hepatocellular carcinoma (HCC) although rarely or not expressed in normal liver tissues, making it a perfect diagnostic and treatment target for HCC. Several GPC3-based clinical trials are ongoing and recently several innovative GPC3-targeted therapeutic methods have emerged with exciting results, including GPC3 vaccine, anti-GPC3 immunotoxin, combined therapy with immune checkpoint blockades (ICBs), and chimeric antigen receptor (CAR) T or NK cells. Here, we review the value of GPC3 in the diagnosis and prognosis of HCC, together with its signaling pathways, with a specific focus on GPC3-targeted treatments of HCC and some prospects for the future GPC3-based therapeutic strategies in HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI